2018
Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease: Physiology-Stratified Analysis of ORBITA
Al-Lamee R, Howard JP, Shun-Shin MJ, Thompson D, Dehbi HM, Sen S, Nijjer S, Petraco R, Davies J, Keeble T, Tang K, Malik IS, Cook C, Ahmad Y, Sharp ASP, Gerber R, Baker C, Kaprielian R, Talwar S, Assomull R, Cole G, Keenan NG, Kanaganayagam G, Sehmi J, Wensel R, Harrell FE, Mayet J, Thom SA, Davies JE, Francis DP. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease: Physiology-Stratified Analysis of ORBITA. Circulation 2018, 138: circulationaha.118.033801. PMID: 29789302, DOI: 10.1161/circulationaha.118.033801.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-1 Receptor AgonistsAgedAngina, StableCardiac CatheterizationCoronary AngiographyCoronary Artery DiseaseCoronary StenosisDobutamineEchocardiography, StressExercise TestExercise ToleranceFemaleFractional Flow Reserve, MyocardialHealth StatusHumansMaleMiddle AgedPercutaneous Coronary InterventionPredictive Value of TestsProgression-Free SurvivalQuality of LifeRecovery of FunctionSeverity of Illness IndexTime FactorsUnited KingdomConceptsPercutaneous coronary interventionInstantaneous wave-free ratioFractional flow reserveSingle-vessel coronary artery diseaseTreadmill exercise timeCoronary artery diseaseExercise timeEchocardiography scoreStable anginaCoronary interventionArtery diseaseFlow reserveCanadian Cardiovascular Society class IIEffect of PCISevere single-vessel diseaseSingle-vessel coronary diseaseMean fractional flow reserveAngina frequency scorePlacebo-controlled effectsPlacebo-controlled efficacyPlacebo-controlled trialTotal exercise timeSingle-vessel diseaseAngina severityEchocardiographic improvement
2017
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial
Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, Keeble T, Mielewczik M, Kaprielian R, Malik IS, Nijjer SS, Petraco R, Cook C, Ahmad Y, Howard J, Baker C, Sharp A, Gerber R, Talwar S, Assomull R, Mayet J, Wensel R, Collier D, Shun-Shin M, Thom SA, Davies JE, Francis DP, investigators O, Al-Lamee R, Thompson D, Sen S, Tang K, Davies J, Keeble T, Kaprielian R, Malik I, Nijjer S, Petraco R, Cook C, Ahmad Y, Howard J, Shun-Shin M, Sethi A, Baker C, Sharp A, Ramrakha P, Gerber R, Talwar S, Assomull R, Foale R, Mayet J, Wensel R, Thom S, Davies J, Francis D, Khamis R, Hadjiloizou N, Khan M, Kooner J, Bellamy M, Mikhail G, Clifford P, O'Kane P, Levy T, Swallow R. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. The Lancet 2017, 391: 31-40. PMID: 29103656, DOI: 10.1016/s0140-6736(17)32714-9.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionPlacebo procedureExercise timeBiomedical Research CentrePlacebo groupPrimary endpointStable anginaCoronary interventionTrials of PCISingle-vessel stenosisMajor bleeding eventsSerious adverse eventsCardiopulmonary exercise testingDobutamine stress echocardiographySevere coronary stenosisInstantaneous wave-free ratioFractional flow reserveBleeding eventsPCI groupIschemic symptomsAdverse eventsExercise testingMedication optimizationAngina reliefRelated complications